Additionally, pharmaceutical giant Abbott Laboratories sold 20.3 million shares of Mylan, removing potential share overhang and Abbot’s position as a large shareholder.
“This return of capital to our shareholders comes at a time of positive momentum for Mylan, with the recent launches and approvals of several key products, our strong future growth expectations, and our belief that the diversified and unique platform we have built is substantially undervalued,” the company said in a statement.
More articles on supply chain:
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
California city could be first in US to use drones to deliver blood
Mold-contaminated antibiotic recalled nationwide: 5 things to know
